Lee's Pharmaceutical Holdings Croissance future

Future contrôle des critères 0/6

Nous ne disposons actuellement pas d'une couverture d'analyste suffisante pour prévoir la croissance et les revenus de Lee's Pharmaceutical Holdings.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	10.8%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Recent updates

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

Sep 04

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Aug 07

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

May 21

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Dec 20

Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Mar 17

Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

Feb 22

What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 29

What Type Of Shareholders Own The Most Number of Lee's Pharmaceutical Holdings Limited (HKG:950) Shares?

Jan 12

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme Lee's Pharmaceutical Holdings n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

SEHK:950 - Estimations futures des analystes et données financières antérieures (HKD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2024	1,199	63	14	130	N/A
3/31/2024	1,126	40	-8	120	N/A
12/31/2023	1,053	17	-30	110	N/A
9/30/2023	980	5	N/A	N/A	N/A
6/30/2023	1,096	39	-133	70	N/A
3/31/2023	1,165	39	N/A	N/A	N/A
12/31/2022	1,233	51	70	284	N/A
9/30/2022	1,350	-119	N/A	N/A	N/A
6/30/2022	1,331	-140	103	317	N/A
3/31/2022	1,308	1,966	N/A	N/A	N/A
12/31/2021	1,266	1,987	-160	211	N/A
9/30/2021	1,275	2,176	N/A	N/A	N/A
6/30/2021	1,244	2,188	-65	394	N/A
3/31/2021	1,227	130	N/A	N/A	N/A
12/31/2020	1,217	129	-139	219	N/A
9/30/2020	1,199	167	N/A	N/A	N/A
6/30/2020	1,168	184	-142	179	N/A
3/31/2020	1,209	118	N/A	N/A	N/A
12/31/2019	1,219	126	39	400	N/A
9/30/2019	1,185	301	N/A	N/A	N/A
6/30/2019	1,177	331	-43	309	N/A
3/31/2019	1,139	395	N/A	N/A	N/A
12/31/2018	1,138	418	27	321	N/A
9/30/2018	1,126	243	N/A	N/A	N/A
6/30/2018	1,101	233	45	447	N/A
3/31/2018	1,064	256	N/A	N/A	N/A
12/31/2017	1,009	233	N/A	366	N/A
9/30/2017	981	245	N/A	N/A	N/A
6/30/2017	955	256	N/A	358	N/A
3/31/2017	930	245	N/A	N/A	N/A
12/31/2016	930	252	N/A	395	N/A
9/30/2016	911	259	N/A	N/A	N/A
6/30/2016	894	247	N/A	309	N/A
3/31/2016	917	242	N/A	N/A	N/A
12/31/2015	922	229	N/A	160	N/A
9/30/2015	976	221	N/A	N/A	N/A
6/30/2015	990	209	N/A	140	N/A
3/31/2015	979	191	N/A	N/A	N/A
12/31/2014	955	193	N/A	220	N/A
9/30/2014	874	175	N/A	N/A	N/A
6/30/2014	805	164	N/A	255	N/A
3/31/2014	755	160	N/A	N/A	N/A
12/31/2013	697	150	N/A	179	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de 950 est supérieure au taux d'épargne ( 2.3% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de 950 devraient croître plus rapidement que le marché Hong Kong

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de 950 devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de 950 devraient croître plus rapidement que le marché Hong Kong.

Croissance élevée des revenus: Données insuffisantes pour déterminer si les revenus de 950 devraient croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de 950 devrait être élevé dans 3 ans

Lee's Pharmaceutical Holdings Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased by 55% to HK$1.10

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Price target decreased to HK$1.80

Price target decreased to HK$1.80

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Price target decreased to HK$4.85

Recent updates

Investor sentiment improves as stock rises 16%

Board Member recently bought HK$66k worth of stock

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

First half 2024 earnings released: EPS: HK$0.11 (vs HK$0.027 in 1H 2023)

First half dividend of HK$0.02 announced

Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong Kong

Board Member recently bought HK$59k worth of stock

Board Member recently bought HK$117k worth of stock

Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director

Board Member recently bought HK$120k worth of stock

Board Member recently bought HK$61k worth of stock

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

Upcoming dividend of HK$0.01 per share

Board Member recently bought HK$130k worth of stock

Less than half of directors are independent

Final dividend of HK$0.01 announced

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022)

Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024

Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Board Member recently bought HK$123k worth of stock

New minor risk - Market cap size

Board Member recently bought HK$75k worth of stock

Investor sentiment improves as stock rises 15%

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Board Member recently bought HK$50k worth of stock

Board Member recently bought HK$113k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$347k worth of stock

Investor sentiment improves as stock rises 17%

Senior Adviser & Non-Executive Director recently bought HK$110k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$76k worth of stock

Investor sentiment improves as stock rises 18%

Price target decreased by 55% to HK$1.10

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023

First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022)

New minor risk - Market cap size

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director

Upcoming dividend of HK$0.01 per share at 1.3% yield

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021)

Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List

Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021)

Price target decreased to HK$1.80

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022

Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa

Price target decreased to HK$1.80

Upcoming dividend of HK$0.01 per share

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022

Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021)

Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022

Board Member recently bought HK$231k worth of stock

Lee's Pharmaceutical Holdings Limited Announces That Teglutik Obtains Drug Registration Certificate

Board Member recently bought HK$381k worth of stock

First quarter 2022 earnings released: EPS: HK$0.035 (vs HK$0.07 in 1Q 2021)

Lee's Pharmaceutical Holdings Limited's Natulan Obtains Drug Registration Certificate

Upcoming dividend of HK$0.031 per share

Lee's Pharmaceutical Holdings Limited to Report Q1, 2022 Results on May 26, 2022

Price target decreased to HK$4.85

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 19, 2022